Pomerantz LLP has announced an investigation into potential securities fraud claims on behalf of investors in Beta Bionics, Inc. (BBNX), CVRx, and Navan. The investigation follows a significant market reaction to the company's fourth-quarter 2025 results, which revealed a material deceleration in patient acquisition metrics.
Beta Bionics' stock declined 37% following the disclosure that new patient starts in Q4 2025 increased 36% year-over-year, a substantial deceleration from the prior quarter's 68% growth rate. The sharp slowdown in patient growth momentum, which represents a key performance indicator for the medical device company, prompted investor concern regarding the accuracy of prior guidance and management disclosures.
The investigation will examine whether company leadership made material misrepresentations or omissions regarding patient growth trajectories and business performance trends. Pomerantz LLP is gathering information from investors who purchased BBNX securities during the relevant period to determine whether actionable securities claims exist.